目的：探讨莫沙必利对胶囊内镜检查的影响。方法44例疑似小肠疾病患者采用随机数字表法分为观察组和对照组，观察组吞服胶囊内镜前15min口服5mg莫沙必利，对照组未服用任何促胃肠动力药，检查当日两组肠道准备相同。比较两组全小肠检查完成率、胶囊内镜通过胃及小肠的时间、小肠清洁度和病变检出率的差异。结果总体全小肠检查完成率为88.6%，观察组为95.5%，对照组为81.8%，差异无统计学意义（P＜0.05）。观察组平均胃通过时间为（23.4±20.9） min，明显短于对照组的（47.4±33.6）min（P＜0.05）；观察组平均小肠通过时间为（216.2±101.5）min，对照组为（211.8±91.3） min，差异无统计学意义（P＞0.05）。观察组胶囊内镜图像平均评分为（2.41±0.40）分，明显好于对照组的（1.72±0.39）分（P＜0.05）。观察组小肠病变率为45.5%，明显高于对照组的13.6%。结论胶囊内镜检查前患者口服莫沙必利具有较好的临床疗效。%Objective To investigate the effect of mosapride on capsule endoscopy. Methods 44 cases of patients suspected of small bowel disease were randomly divided into the observation group and the control group ,the observation group took 5mg Mosapride 15 minutes before swallowing capsule endoscopy,the control group did not take any prokinetic agents,two groups had the same bowel preparation in checking. Compared the differences between the two groups in the complete small bowel examination rate,stomach and small intestinal transit time,intestinal cleanness and the detection rate of lesions. Results The total complete small bowel examination rate was 88.6%,95.5% in the observation group,81.8% in the control group, there were no significant differences between the two groups(P<0.05). The average gastric transit time of observation group was (23.4± 20.9) minutes,significantly shorter than the control group (P<0.05). The average small intestinal transit time of observation group was (216.2±101.5) minutes,the control group was (211.8±91.3) minutes,there were no significant differences between the two groups (P>0.05). Capsule endoscopy image mean score of the observation group was (2.41±0.40) points, significantly better than the control group (P<0.05). The small bowel disease detection rate of the observation group was 45.5%,significantly higher than the control group. Conclusion Taking oraling mosapride before capsule endoscopy has better clinical effect.
展开▼
